MGF vs YK11

Evidence-based comparison · Updated 2026

Summary

MGF is better suited for localized, post-exercise muscle repair through paracrine IGF-1 signaling, while YK11 targets systemic muscle growth via androgen receptor modulation and myostatin inhibition. Researchers focused on site-specific hypertrophy and satellite cell activation may favor MGF, whereas those investigating broad muscle mass increases and follistatin pathway modulation may lean toward YK11. Both are research-only compounds with limited human safety data.

Side-by-Side Comparison

	MGF	YK11
Evidence	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence
Regulatory	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits	+Promotes localized muscle repair and growth +Enhances muscle protein synthesis post-exercise +Supports recovery from mechanical stress +Stimulates satellite cell activation +May improve muscle hypertrophy response	+Increases muscle mass and strength +Enhances follistatin expression +Improves muscle protein synthesis +Supports lean body composition +May enhance athletic performance
Dosage	100-200 mcg — 1x daily	5-10 mg — 1x daily
Route	Subcutaneous	Subcutaneous
Category	Muscle Growth & Performance	Muscle Growth & Performance

Full research page

MGF →

Full research page

YK11 →

Which Should You Choose?

MGF operates through a localized paracrine mechanism tied to mechanical stress responses, while YK11 acts systemically through androgen receptor pathways and myostatin suppression, making them mechanistically distinct tools for muscle research.

Choose MGF when:

+Research focus involves localized muscle repair at specific injection sites following mechanical loading or exercise protocols
+Study design requires activation of satellite cells and myoblast proliferation as primary endpoints rather than systemic anabolic signaling
+Interest in IGF-1 splice variant biology and post-exercise protein synthesis without engaging the androgen receptor pathway

Choose YK11 when:

+Research objective involves systemic increases in lean muscle mass through dual androgen receptor modulation and myostatin inhibition
+Study design targets follistatin upregulation as a measurable mechanistic endpoint for myostatin pathway suppression
+Investigation requires a compound with tissue-selective androgenic activity distinct from traditional anabolic steroids, accepting limited human safety data

Stacking MGF with YK11 is theoretically discussed in research contexts because their mechanisms are complementary, with MGF addressing localized satellite cell activation and YK11 providing systemic myostatin suppression, though no peer-reviewed human studies have evaluated this combination.

Frequently Asked Questions

Do MGF and YK11 work through overlapping pathways, or are they fully independent mechanisms?⌄

These two compounds operate through largely independent pathways. MGF signals locally via IGF-1 receptor interactions to recruit satellite cells and drive localized myoblast differentiation, while YK11 engages the androgen receptor and suppresses myostatin by upregulating follistatin. There is no known direct mechanistic overlap, which is why some researchers consider them potentially complementary rather than redundant when studied together.

How do the research timelines for observing results differ between MGF and YK11?⌄

MGF's effects on satellite cell activation and localized protein synthesis are expected to occur in the acute post-exercise window, with most preclinical models assessing outcomes over days to a few weeks following mechanical stress induction. YK11's effects on follistatin expression and muscle mass accumulation are generally studied over longer durations, typically several weeks, reflecting the slower kinetics of myostatin pathway suppression and androgen-mediated hypertrophy. Researchers should account for these differing timelines when designing comparative protocols.

Which compound carries greater safety uncertainty for research use, MGF or YK11?⌄

YK11 carries a lower evidence grade (D) compared to MGF (C), reflecting its more limited research base and greater uncertainty around safety, particularly regarding androgenic side effects and long-term hormonal impact. MGF, while also research-only, has a broader preclinical literature supporting its mechanism and tolerability profile in animal models. Neither compound has sufficient human clinical trial data to characterize a full safety profile, and both are strictly for non-human research use.

Is there a meaningful difference in administration considerations between MGF and YK11 for research protocols?⌄

MGF is typically administered via localized intramuscular injection near the target muscle tissue to leverage its paracrine signaling mechanism, making injection site selection a critical protocol variable. YK11, being investigated for systemic effects through androgen receptor and myostatin pathways, is generally studied with oral or systemic administration routes. This difference in delivery strategy reflects each compound's mechanism and should be factored into experimental design when comparing or combining them.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500 mots c vs semaglutide dsip vs melanotan ii retatrutide vs tirzepatide cjc 1295 vs ipamorelin